Premium
Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non‐canonical tumour‐associated mucin 1‐8 peptide
Author(s) -
Lazoura Eliada,
Lodding Jodie,
Farrugia William,
Ramsland Paul A.,
Stevens James,
Wilson Ian A.,
Pietersz Geoffrey A.,
Apostolopoulos Vasso
Publication year - 2006
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2006.02434.x
Subject(s) - major histocompatibility complex , peptide , immune system , antigen , biology , t cell receptor , mhc restriction , mhc class i , t cell , epitope , muc1 , immunotherapy , cytotoxic t cell , immunology , microbiology and biotechnology , biochemistry , in vitro
Summary Designing peptide‐based vaccines for therapeutic applications in cancer immunotherapy requires detailed knowledge of the interactions between the antigenic peptide and major histocompatibility complex (MHC) in addition to that between the peptide–MHC complex and the T‐cell receptor. Past efforts to immunize with high‐affinity tumour‐associated antigenic peptides have not been very immunogenic, which may be attributed to the lack of T cells to these peptides, having been deleted during thymic development. For this reason, low‐to‐medium affinity non‐canonical peptides represent more suitable candidates. However, in addition to the difficulty in identifying such antigens, peptide binding to MHC, and hence its ability to induce a strong immune response, is limited. Therefore, to enhance binding to MHC and improve immune responses, anchor modifications of non‐canonical tumour‐associated peptides would be advantageous. In this study, the non‐canonical tumour‐associated peptide from MUC1, MUC1‐8 (SAPDTRPA), was modified at the MHC anchor residues to SAPDFRPL (MUC1‐8‐5F8L) and showed enhanced binding to H‐2K b and improved immune responses. Furthermore, the crystal structure of MUC1‐8‐5F8L in complex with H‐2K b was determined and it revealed that binding of the peptide to MHC is similar to that of the canonical peptide OVA8 (SIINFEKL).